Clinical Trial Search

Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2

Primary: Progression Free Survival (PFS) — 15.4; 14.3 Months — p=0.31

Primary: PFS — 29.8 Months

Primary: Objective Response Rate (ORR) — 2; 0 Participants

Primary: Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab — 7 protocol defined adverse events

Primary: Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population…

Primary: Best Overall Response and Objective Response Rate Following Treatment With CS-1008 in Combination With Chemotherapy (Paclitaxel/Carboplatin) in Locally Advanced or…

Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants

Primary: 2-year Progression-free Survival — 40; 40 percentage of participants

Primary: Clinical Response Rate. — 0; 19; 21; 60 percentage of participants

Primary: Pathologic Complete Response Rates — 8 participants

Primary: Tumor Response Type: CR, PR, SD or PD — 1; 4; 9; 6 Participants

Primary: Response Rate — 1; 2; 4 participants

Primary: Phase 1b: Recommended Phase 2 Dose of LY2228820 in Combination With Gemcitabine and Carboplatin (Maximum Tolerated Dose [MTD]) — 200 milligrams (mg)

Primary: Percentage of Participants With Complete Response and Partial Response (Objective Response Rate) — 7.5; 0; 3.1 percentage of participants

Primary: Progression Free Survival (PFS) Rate at 6 Months — 55.2 percentage of patients

Primary: Complete and Partial Response Rate Using the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria — 2; 11; 1; 8 participants

Primary: Progression-free Survival (PFS) — 7.2; 13.0 months

Primary: The Percentage of Patients Who Survive Progression Free for at Least 6 Months — 23 percentage of participants

Primary: Progression-free Survival — 2.9; 5.3 months — p=0.019

Primary: Four Cycle Progression-free Survival Rate — 8 Participants

Primary: Progression-free Survival (PFS) — 56 percentage of participants

Primary: Overall Response Rate (ORR) — 0; 0 participants

Primary: Progression Free Survival (PFS) — 20.0; 22.2 Months — p=0.199

Primary: Overall Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors and by Rustin's Criteria (RECIST) — 4; 5; 9; 4 Participants

Primary: Progression-free Survival (PFS) — 13.7; 8.4 months

Primary: Consolidation Progression-Free Survival — 13.3; 18.9 months

Primary: Overall Response Rate (ORR) — 4 participants

Primary: Progression-free Survival at 6 Months — 40.3 percentage of participants

Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants